Cargando…

Proteomic patterns associated with response to breast cancer neoadjuvant treatment

Tumor relapse as a consequence of chemotherapy resistance is a major clinical challenge in advanced stage breast tumors. To identify processes associated with poor clinical outcome, we took a mass spectrometry‐based proteomic approach and analyzed a breast cancer cohort of 113 formalin‐fixed paraffi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shenoy, Anjana, Belugali Nataraj, Nishanth, Perry, Gili, Loayza Puch, Fabricio, Nagel, Remco, Marin, Irina, Balint, Nora, Bossel, Noa, Pavlovsky, Anya, Barshack, Iris, Kaufman, Bella, Agami, Reuven, Yarden, Yosef, Dadiani, Maya, Geiger, Tamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507992/
https://www.ncbi.nlm.nih.gov/pubmed/32960509
http://dx.doi.org/10.15252/msb.20209443
_version_ 1783585339343896576
author Shenoy, Anjana
Belugali Nataraj, Nishanth
Perry, Gili
Loayza Puch, Fabricio
Nagel, Remco
Marin, Irina
Balint, Nora
Bossel, Noa
Pavlovsky, Anya
Barshack, Iris
Kaufman, Bella
Agami, Reuven
Yarden, Yosef
Dadiani, Maya
Geiger, Tamar
author_facet Shenoy, Anjana
Belugali Nataraj, Nishanth
Perry, Gili
Loayza Puch, Fabricio
Nagel, Remco
Marin, Irina
Balint, Nora
Bossel, Noa
Pavlovsky, Anya
Barshack, Iris
Kaufman, Bella
Agami, Reuven
Yarden, Yosef
Dadiani, Maya
Geiger, Tamar
author_sort Shenoy, Anjana
collection PubMed
description Tumor relapse as a consequence of chemotherapy resistance is a major clinical challenge in advanced stage breast tumors. To identify processes associated with poor clinical outcome, we took a mass spectrometry‐based proteomic approach and analyzed a breast cancer cohort of 113 formalin‐fixed paraffin‐embedded samples. Proteomic profiling of matched tumors before and after chemotherapy, and tumor‐adjacent normal tissue, all from the same patients, allowed us to define eight patterns of protein level changes, two of which correlate to better chemotherapy response. Supervised analysis identified two proteins of proline biosynthesis pathway, PYCR1 and ALDH18A1, that were significantly associated with resistance to treatment based on pattern dominance. Weighted gene correlation network analysis of post‐treatment samples revealed that these proteins are associated with tumor relapse and affect patient survival. Functional analysis showed that knockdown of PYCR1 reduced invasion and migration capabilities of breast cancer cell lines. PYCR1 knockout significantly reduced tumor burden and increased drug sensitivity of orthotopically injected ER‐positive tumor in vivo, thus emphasizing the role of PYCR1 in resistance to chemotherapy.
format Online
Article
Text
id pubmed-7507992
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75079922020-09-28 Proteomic patterns associated with response to breast cancer neoadjuvant treatment Shenoy, Anjana Belugali Nataraj, Nishanth Perry, Gili Loayza Puch, Fabricio Nagel, Remco Marin, Irina Balint, Nora Bossel, Noa Pavlovsky, Anya Barshack, Iris Kaufman, Bella Agami, Reuven Yarden, Yosef Dadiani, Maya Geiger, Tamar Mol Syst Biol Articles Tumor relapse as a consequence of chemotherapy resistance is a major clinical challenge in advanced stage breast tumors. To identify processes associated with poor clinical outcome, we took a mass spectrometry‐based proteomic approach and analyzed a breast cancer cohort of 113 formalin‐fixed paraffin‐embedded samples. Proteomic profiling of matched tumors before and after chemotherapy, and tumor‐adjacent normal tissue, all from the same patients, allowed us to define eight patterns of protein level changes, two of which correlate to better chemotherapy response. Supervised analysis identified two proteins of proline biosynthesis pathway, PYCR1 and ALDH18A1, that were significantly associated with resistance to treatment based on pattern dominance. Weighted gene correlation network analysis of post‐treatment samples revealed that these proteins are associated with tumor relapse and affect patient survival. Functional analysis showed that knockdown of PYCR1 reduced invasion and migration capabilities of breast cancer cell lines. PYCR1 knockout significantly reduced tumor burden and increased drug sensitivity of orthotopically injected ER‐positive tumor in vivo, thus emphasizing the role of PYCR1 in resistance to chemotherapy. John Wiley and Sons Inc. 2020-09-22 /pmc/articles/PMC7507992/ /pubmed/32960509 http://dx.doi.org/10.15252/msb.20209443 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Shenoy, Anjana
Belugali Nataraj, Nishanth
Perry, Gili
Loayza Puch, Fabricio
Nagel, Remco
Marin, Irina
Balint, Nora
Bossel, Noa
Pavlovsky, Anya
Barshack, Iris
Kaufman, Bella
Agami, Reuven
Yarden, Yosef
Dadiani, Maya
Geiger, Tamar
Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title_full Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title_fullStr Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title_full_unstemmed Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title_short Proteomic patterns associated with response to breast cancer neoadjuvant treatment
title_sort proteomic patterns associated with response to breast cancer neoadjuvant treatment
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507992/
https://www.ncbi.nlm.nih.gov/pubmed/32960509
http://dx.doi.org/10.15252/msb.20209443
work_keys_str_mv AT shenoyanjana proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT belugalinatarajnishanth proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT perrygili proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT loayzapuchfabricio proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT nagelremco proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT marinirina proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT balintnora proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT bosselnoa proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT pavlovskyanya proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT barshackiris proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT kaufmanbella proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT agamireuven proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT yardenyosef proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT dadianimaya proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment
AT geigertamar proteomicpatternsassociatedwithresponsetobreastcancerneoadjuvanttreatment